SlideShare a Scribd company logo
The Current And Future Potential
Applications Of PET/MR Imaging
In Neurodegenerative Diseases
By
Dr. Walid Rezk, M.D.
Lecturer of Radiodiagnosis
Ain Shams University
 Neurodegenerative disorders such as Alzheimer
disease are among today’s most alarming health
problems in our aging society.
 The clinical assessment of neurodegenerative
disorders benefits from recent innovations in the field
of imaging technology.
 These innovations include emerging tracers for
molecular imaging of neuro-degenerative pathology
and the introduction of novel integrated PET/MR
imaging instruments.
Introduction
 Neurodegenerative diseases are characterized by a
progressive and chronic loss of neural tissue in cognitive,
motor, sensory, and other brain systems.
 This entity of diseases includes:
o Dementias
o Parkinsonian syndromes including movement diseases
such as multisystem atrophies (MSA), cortical-basal
degeneration (CBD), and progressive supranuclear
palsy (PSP)
o Huntington disease (HD)
o Amyotrophic lateral sclerosis (ALS)
o Prion diseases like Creutzfeldt-Jakobdisease (CJD)
Neurodegenerative disorders
 In daily routine, most neurodegenerative diseases are
diagnosed by a combination of clinical testing
together with biomarkers, like brain imaging or
cerebrospinal fluid analysis.
 In brain imaging of neurodegenerative disease, MRI
represents the standard tool. This is based on the
high spatial resolution and the high soft tissue
contrast this modality offers as well as the rather
specific findings in at least some movement disorders
such as MSA and PSP.
 Often MRI is employed in suspected
neurodegenerative diseases to exclude other non-
neurodegenerative causes for the symptoms
observed, like vascular disease, brain tumors, and
traumatic or inflammatory brain changes.
 In addition, certain brain atrophy patterns may
support the clinical diagnosis of distinct
neurodegenerative diseases.
 Brain PET has also been used over many years to
diagnose neurodegenerative diseases.
 The main advantage of PET over MRI lies in its higher
sensitivity to detect pathologies on a molecular level,
which at least in principle permits more sensitive or
even earlier diagnoses, because these diseases start
with pathobiochemical processes that only lead to
morphologic changes visible on MRI after a certain
time period.
Current PET Tracers to Image
Neurodegenerative Diseases
 It is evident that [18F]FDG, which is transported into
intracellular space by glucose 1 transporters followed
by phosphorylation via the hexokinase reaction, is the
most often employed PET tracer in this regard.
 [18F]FDG represents a universal marker of neuronal
and synaptic integrity with relatively disease-specific
uptake reduction patterns as for example:
AD: bilateral temporoparietal areas are mainly
affected exhibit [18 F]FDG uptake reductions.
o Frontotemporal lobar
degeneration (FTLD) in
which, depending on its
subtype, mainly frontal
region or temporal
region or both exhibit
[18 F]FDG uptake
reductions.
o Parkinsonism: [18F]FDG-PET allows discrimination
between primary PD and atypical parkinsonian
syndromes, as major glucose consumption deficits
being only found in the latter.
o HD: mainly showing striatal uptake reduction
o ALS: showing variable uptake reduction patterns
depending on the ALS subtypes.
 CJD: showing patchy uptake reductions of different
patterns throughout the cortex and subcortical
structures.
 Apart from [18F]FDG, two groups of more disease-
specific PET tracers are currently available in clinical
routine:
1. Amyloid plaque tracers:
 In AD, β-amyloid plaques, one of the
histopathologically hallmarks of the disease,
recently became traceable by PET tracers, like [18F]
florbetapir, [18F] florbetaben, or [18F] flutemetamol.
 These tracers are now approved for clinical use and
are currently employed to show or exclude brain
amyloid load in mild cognitive impairment (MCI), and
early-onset clinical presentation of AD-like dementia.
2. PET tracers that target different components of
dopaminergic transmission:
Dopamine precursor tracer 3,4-dihydroxy-6-[18F]-
fluorol-phenylalanine ([18F] FDOPA)
The presynaptic dopamine transporter (DAT)-
targeting [18F] fluoropropyl carbomethoxy
iodophenylnortropane (FP-CIT)
Both are used for clinical routine purposes to
diagnose parkinsonian syndromes
 In the scan of a disease-free brain, made with [18F]-
FDOPA PET (left image), the red and yellow areas show
the dopamine concentration in a normal putamen.
Compared with that scan, a similar scan of a
Parkinson’s patient (right image) shows a marked
dopamine deficiency in the putamen.
Current MRI Techniques to Image
Neurodegenerative Diseases
Disease Typical MRI Sequences
Alzheimer disease T2 FLAIR and T1 3D GRE
FTLD FLAIR and T1 3D GRE
Vascular dementia FLAIR, T2*/SWI, and DWI
DLB FLAIR and T1 3D GRE
Parkinson disease T1, T2 multiplanar, and T2*/SWI
Atypical parkinsonian syndromes T1, T2 multiplanar, and T2*/SWI
Huntington disease T1, T2, and T2*/SWI
ALS T1 and T2
CJD DWI, FLAIR, T1, and T2
Current Clinical Routine MRI Sequences to Image
Neurodegenerative Diseases
The routine MR imaging may reveal specific pattern of
atrophy as in:
 AD: Temporal atrophy patterns according to
established scores (Scheltens score)
 PSP: mesencephalic
atrophy (mickey mouse
sign)
 Cerebellar MSA (formerly known as olivopontine
cerebellar atrophy): pontine and cerebellar atrophy
patterns combined with distinctive signs of pontine
neurodegeneration (hot cross bun sign)
 Advanced stages of HD: isolated putamen and
caudate head atrophy
 Hallervorden-Spatz
disease, and
occasionally PSP and
CBD: iron
accumulation with
gliosis and
spongiosis of the
pallidum (eye-of-
the-tiger sign)
 Parkinsonian MSA (formerly known as MSA-
striatonigral degeneration): periputaminal gliosis
 CBD: unilateral atrophy of the primary motor cortex
together with cortico-spinal tract degeneration
 Diffusion-weighted MRI may show typical signal
changes of the basal ganglia and cortex in CJD with
greater visibility than on T2-weighted images owing
to restricted diffusion with extracellular edema
Combined PET/MRI to Image
Neurodegenerative Diseases
 Taking the aforementioned status and advantages of
both PET and MR to image neurodegenerative
diseases, it was a logical early step to clinically test
the potential of combined PET/MRI technology in
improving and simplifying neurodegeneration
imaging.
 One of the main technical challenges of integrated
PET/MRI is to find a reliable substitute for the standard
transmission-based (CT or line sources) attenuation
correction (AC) of the PET data, a technique which is not
available within combined PET/MRI systems.
 In the current PET/MRI systems, AC of the PET data is
mainly accomplished by using a 2-point Dixon MR
sequence that segments tissues into four classes (lung, air,
fat, and soft tissue) and is in some systems supplemented
or substituted by an ultrashort echo time (UTE) sequence
that provides additional bone contrast or segmentation.
 An MR localizer precedes an approximately 20-
minutes data acquisition interval in which a PET
emission scan is simultaneously obtained with an
array of MR sequences
 Dixon or UTE sequences or both for AC of the PET
data
 T2 Fluid-attenuated inversion recovery sequence to
decide on the extent of vascular lesions and atrophy
Protocol of PET/MR examination
 T2 turbo spin-echo sequences to give optimal
contrast to infratentorial structures and to evaluate
atrophy
 Susceptibility-weighted sequence to detect
microbleeds
 T1-magnetization–prepared rapid acquisition gradient
echo sequence for further, also quantitative,
anatomical imaging and potential morphometric
analysis.
Protocol of PET/MR examination
 Left two columns, represent amyloid PET/MR overlay together with the z-
score map illustrating pathologic neocortical amyloid plaque burden (AD,
DLB) or normal tracer uptake (VaD)
 Middle column, the corresponding transverse anatomical T1-magnetization–
prepared rapid acquisition gradient echo (MPRAGE) MR slice.
 Right two columns, the corresponding transverse slices of other imaging
modalities demonstrating biparietotemporal glucose consumption deficits
(AD, DLB) or periventricular vascular lesions (VaD).
 Severe bilateral
hippocampal atrophy
evident by severely
reduced hippocampal
volume (white arrows)
(Left more than right) on
Axial MRI images (A)
With prominent bilateral
frontal and temporal
hypometabolism on axial
fused PET MRI images
(white arrowhead) (B
and C). Note preserved
parietal metabolism on
axial and sagittal fused
PET MRI images (white
thick arrows) (D)
 By obtaining all required imaging and biomarker
information within one session, not just an improved
convenience to the patients and their caregivers but
also to the referring doctors is anticipated.
 Furthermore, combined PET/MRI is expected to
improve the diagnostic quality of both modalities by
allowing simultaneous image data acquisition as well
as a simplified and more accurate (owing to the
perfect match between the PET and MRI data) image
data analysis.
Advantages of PET/MRI
 Head movements during data acquisition can be
online monitored by MRI, allowing for improved
motion correction of the PET data.
 Further, the MR information can be used to correct
PET data for atrophy and partial volume effects.
 Also, PET tracer uptake quantification can be
improved by considering MRI-derived information on
lean body mass, by creating an image-derived arterial
input function, as well as by considering factors
influencing brain tracer supply, like cerebral blood
flow.
Advantages of PET/MRI
 Vice versa, the testing and evaluation of new MR
techniques can be improved by validating them
against simultaneously acquired PET gold standard
techniques. Examples of that are ASL, which is tested
in patients with dementia as a substitute for [18F]
FDG, or quantitative susceptibility mapping as a
potential substitute for amyloid PET tracers.
Advantages of PET/MRI
Future Potential of PET/MRI in
Neuro-degenerative Diseases
 For dementia imaging, there are promising new PET
tracers as well as MR sequence developments.
 For the PET component, the new emergence of tau
tracers and α-synuclein tracers is attractive, as they
will increase the possibilities to visualize different
histopathologic hallmarks of different underlying
dementias.
Future Potential of PET/MRI in
Dementia Diseases
 Regarding newer potential MR techniques, especially
diffusion-tensor imaging (DTI), resting-state
functional MRI (rs-fMRI), and perfusion imaging are
considered promising candidates to improve
dementia diagnosis.
 DTI maps showing white matter fiber integrity are
able to provide models of structural brain
connectivity, features that are often disturbed in
neuro-degenerative diseases.
 Rs-fMRI may provide complementary information
about functional connectivity and allow functional
cerebral network analysis.
 Perfusion MRI, either traditionally using contrast-
enhancement or arterial spin labeling (ASL), is
another attractive approach.
 In combination with amyloid PET tracers, at least in
principle, the collection of information on both
biomarker categories (amyloid load and neuronal
injury) in AD within one session is possible
 Novel PET tracers especially targeting DATs and α-
synuclein are in development, potentially opening the
way for a wider use of PET and PET/MRI as first-line
imaging in these neurodegenerative diseases.
Future Potential of PET/MRI in
Parkinsonian Syndromes
 For MRI, standard anatomical imaging as currently
employed in most situations to detect specific
atrophy patterns for different atypical parkinsonian
syndromes might be enriched in the future by routine
voxel-based morphometry and new techniques to
detect and quantify white matter fiber degeneration
and structural connectivity deficiency (DTI), and iron
accumulation, for instance in midbrain or striatal
areas (iron mapping)
Future Potential of PET/MRI in Other
Neurodegenerative Diseases
 There are promising new developments regarding
new PET tracers and novel MR sequences to improve
imaging of these diseases.
 Some of the new emerging PET tracers target
neuroinflammatory processes known to occur in HD
or ALS,
 whereas others include more disease-specific
processes like prion amyloid plaques in CJD.
Take home message
 The recently established combined PET/MRI
technology has a great but yet mostly unexplored
potential to improve early and differential diagnosis
of many neuro-degenerative diseases.
 New emerging PET tracers, like tracers that bind to β-
amyloid, tau, or α-synuclein aggregates, as well as
new MR techniques, like DTI, rs-fMRI, or ASL, will
broaden the diagnostic capabilities of combined
PET/MRI.
 From the current knowledge on applying combined
PET/MRI in neurodegenerative diseases, it is
concluded that there is a chance of establishing this
technique as routine first-line one-stop-shop clinical
imaging tool.
 Basic research into neurodegenerative diseases and
antineurodegeneration drug testing are considered
other promising applications of combined PET/MRI
Thank you

More Related Content

What's hot

MR Spectroscopy
MR SpectroscopyMR Spectroscopy
MR Spectroscopy
NeurologyKota
 
SPOTTERS IN NEUROLOGY
SPOTTERS IN NEUROLOGYSPOTTERS IN NEUROLOGY
SPOTTERS IN NEUROLOGY
NeurologyKota
 
Presentation1.pptx, radiological imaging of dementia.
Presentation1.pptx, radiological imaging of dementia.Presentation1.pptx, radiological imaging of dementia.
Presentation1.pptx, radiological imaging of dementia.Abdellah Nazeer
 
Functional neuroimaging.pptx
Functional neuroimaging.pptx Functional neuroimaging.pptx
Functional neuroimaging.pptx
NeurologyKota
 
Normal anatomy of brain on CT and MRI
Normal anatomy of brain on CT and MRINormal anatomy of brain on CT and MRI
Normal anatomy of brain on CT and MRI
Dr Anuj Aggarwal
 
Presentation1, radiological imaging of leigh disease.
Presentation1, radiological imaging of leigh disease.Presentation1, radiological imaging of leigh disease.
Presentation1, radiological imaging of leigh disease.
Abdellah Nazeer
 
Diffusion tensor imaging in Neurology
Diffusion tensor imaging in NeurologyDiffusion tensor imaging in Neurology
Diffusion tensor imaging in Neurology
Osama Ragab
 
IMAGING OF INTRAVENTRICULAR TUMORS
IMAGING OF INTRAVENTRICULAR TUMORS IMAGING OF INTRAVENTRICULAR TUMORS
IMAGING OF INTRAVENTRICULAR TUMORS
Ameen Rageh
 
imaging in neurology - demyelinating diseases
 imaging in neurology - demyelinating diseases imaging in neurology - demyelinating diseases
imaging in neurology - demyelinating diseases
NeurologyKota
 
Brain tumor imaginig 3 10th may 02
Brain tumor imaginig   3  10th may 02Brain tumor imaginig   3  10th may 02
Brain tumor imaginig 3 10th may 02PS Deb
 
Clinical correlation and interpretation of Brain MRI by dr.Sagor
Clinical correlation and interpretation of Brain MRI by dr.SagorClinical correlation and interpretation of Brain MRI by dr.Sagor
Clinical correlation and interpretation of Brain MRI by dr.Sagor
Chittagong Medical College Hospital
 
Diagnostic Imaging of Brain Tumors
Diagnostic Imaging of Brain TumorsDiagnostic Imaging of Brain Tumors
Diagnostic Imaging of Brain Tumors
Mohamed M.A. Zaitoun
 
Radiological Evaluation of CNS Tumors
Radiological Evaluation of CNS TumorsRadiological Evaluation of CNS Tumors
Radiological Evaluation of CNS Tumors
Subhash Thakur
 
Mri of muscle diseases
Mri of  muscle diseasesMri of  muscle diseases
Mri of muscle diseasesSarath Menon
 
Pediatric neuroimaging
Pediatric neuroimagingPediatric neuroimaging
Pediatric neuroimaging
Krishna Kiran Karanth
 
Myelination disorders
Myelination disordersMyelination disorders
Myelination disorders
Anish Choudhary
 
Pineal tumors
Pineal tumorsPineal tumors
Pineal tumors
Usman Haqqani
 
Imaging in SAH
Imaging  in  SAHImaging  in  SAH
Imaging in SAH
Sarath Menon
 
Presentation1.pptx, radiological imaging of peri natal acute ischemia and hyp...
Presentation1.pptx, radiological imaging of peri natal acute ischemia and hyp...Presentation1.pptx, radiological imaging of peri natal acute ischemia and hyp...
Presentation1.pptx, radiological imaging of peri natal acute ischemia and hyp...Abdellah Nazeer
 

What's hot (20)

MR Spectroscopy
MR SpectroscopyMR Spectroscopy
MR Spectroscopy
 
SPOTTERS IN NEUROLOGY
SPOTTERS IN NEUROLOGYSPOTTERS IN NEUROLOGY
SPOTTERS IN NEUROLOGY
 
Presentation1.pptx, radiological imaging of dementia.
Presentation1.pptx, radiological imaging of dementia.Presentation1.pptx, radiological imaging of dementia.
Presentation1.pptx, radiological imaging of dementia.
 
Functional neuroimaging.pptx
Functional neuroimaging.pptx Functional neuroimaging.pptx
Functional neuroimaging.pptx
 
Normal anatomy of brain on CT and MRI
Normal anatomy of brain on CT and MRINormal anatomy of brain on CT and MRI
Normal anatomy of brain on CT and MRI
 
Presentation1, radiological imaging of leigh disease.
Presentation1, radiological imaging of leigh disease.Presentation1, radiological imaging of leigh disease.
Presentation1, radiological imaging of leigh disease.
 
Diffusion tensor imaging in Neurology
Diffusion tensor imaging in NeurologyDiffusion tensor imaging in Neurology
Diffusion tensor imaging in Neurology
 
IMAGING OF INTRAVENTRICULAR TUMORS
IMAGING OF INTRAVENTRICULAR TUMORS IMAGING OF INTRAVENTRICULAR TUMORS
IMAGING OF INTRAVENTRICULAR TUMORS
 
imaging in neurology - demyelinating diseases
 imaging in neurology - demyelinating diseases imaging in neurology - demyelinating diseases
imaging in neurology - demyelinating diseases
 
Brain tumor imaginig 3 10th may 02
Brain tumor imaginig   3  10th may 02Brain tumor imaginig   3  10th may 02
Brain tumor imaginig 3 10th may 02
 
Clinical correlation and interpretation of Brain MRI by dr.Sagor
Clinical correlation and interpretation of Brain MRI by dr.SagorClinical correlation and interpretation of Brain MRI by dr.Sagor
Clinical correlation and interpretation of Brain MRI by dr.Sagor
 
Diagnostic Imaging of Brain Tumors
Diagnostic Imaging of Brain TumorsDiagnostic Imaging of Brain Tumors
Diagnostic Imaging of Brain Tumors
 
Radiological Evaluation of CNS Tumors
Radiological Evaluation of CNS TumorsRadiological Evaluation of CNS Tumors
Radiological Evaluation of CNS Tumors
 
Mri of muscle diseases
Mri of  muscle diseasesMri of  muscle diseases
Mri of muscle diseases
 
Pediatric neuroimaging
Pediatric neuroimagingPediatric neuroimaging
Pediatric neuroimaging
 
Myelination disorders
Myelination disordersMyelination disorders
Myelination disorders
 
Pineal tumors
Pineal tumorsPineal tumors
Pineal tumors
 
Medulloblastomas
MedulloblastomasMedulloblastomas
Medulloblastomas
 
Imaging in SAH
Imaging  in  SAHImaging  in  SAH
Imaging in SAH
 
Presentation1.pptx, radiological imaging of peri natal acute ischemia and hyp...
Presentation1.pptx, radiological imaging of peri natal acute ischemia and hyp...Presentation1.pptx, radiological imaging of peri natal acute ischemia and hyp...
Presentation1.pptx, radiological imaging of peri natal acute ischemia and hyp...
 

Similar to PET/MR imaging in neurodegenerative diseases

Positron emission tomographic scan
Positron emission tomographic scanPositron emission tomographic scan
Positron emission tomographic scanPrashant Makhija
 
Clinacal applications of PET/CT vs PET/MRI
Clinacal applications of PET/CT vs PET/MRIClinacal applications of PET/CT vs PET/MRI
Clinacal applications of PET/CT vs PET/MRI
Walid Rezk
 
Brain PET imaging
Brain PET imagingBrain PET imaging
Brain PET imaging
Dr- Mustafa Ahmed Alazam
 
Handbook of nuclear cardiology
Handbook of nuclear cardiologyHandbook of nuclear cardiology
Handbook of nuclear cardiologySpringer
 
Pet scan and thyroid scan
Pet scan and thyroid scanPet scan and thyroid scan
Pet scan and thyroid scan
Holy Family Hospital Rawalpindi
 
Positron Emission Tomography (PET).pdf
Positron Emission Tomography (PET).pdfPositron Emission Tomography (PET).pdf
Positron Emission Tomography (PET).pdf
SELF-EXPLANATORY
 
Emerging MRI and metabolic neuroimaging techniques in mild traumatic brain in...
Emerging MRI and metabolic neuroimaging techniques in mild traumatic brain in...Emerging MRI and metabolic neuroimaging techniques in mild traumatic brain in...
Emerging MRI and metabolic neuroimaging techniques in mild traumatic brain in...
IntesarAldweri
 
Medical Imaging In Future Physician
Medical  Imaging In Future  PhysicianMedical  Imaging In Future  Physician
Medical Imaging In Future PhysicianPrabhu Ethiraj
 
PET.pptx
PET.pptxPET.pptx
Neuroimaging in dementia
Neuroimaging in dementiaNeuroimaging in dementia
Neuroimaging in dementia
NeurologyKota
 
PET and SPECT Scanning: Functional Brain Imaging
PET and SPECT Scanning: Functional Brain ImagingPET and SPECT Scanning: Functional Brain Imaging
PET and SPECT Scanning: Functional Brain Imaging
Brendan Quinn
 
Clinical imaging and molecular biomarkers of drug resistant epilepsy.pptx
Clinical imaging and molecular biomarkers of drug resistant epilepsy.pptxClinical imaging and molecular biomarkers of drug resistant epilepsy.pptx
Clinical imaging and molecular biomarkers of drug resistant epilepsy.pptx
Pramod Krishnan
 
Fneur 12-601153
Fneur 12-601153Fneur 12-601153
Fneur 12-601153
BHAYU RIZALLINOOR
 
Basics and principles of PET.pptx
Basics and principles of PET.pptxBasics and principles of PET.pptx
Basics and principles of PET.pptx
OlaAttieh2
 
Diagnosis of CIDP
Diagnosis of CIDPDiagnosis of CIDP
Diagnosis of CIDP
MohamadAlhes
 
Neuroradiology in dementia
Neuroradiology in dementiaNeuroradiology in dementia
Neuroradiology in dementia
NeurologyKota
 
The Expanding Role of Neuroimaging in Alzheimer’s Disease Diagnosis and Manag...
The Expanding Role of Neuroimaging in Alzheimer’s Disease Diagnosis and Manag...The Expanding Role of Neuroimaging in Alzheimer’s Disease Diagnosis and Manag...
The Expanding Role of Neuroimaging in Alzheimer’s Disease Diagnosis and Manag...
PVI, PeerView Institute for Medical Education
 

Similar to PET/MR imaging in neurodegenerative diseases (20)

Positron emission tomographic scan
Positron emission tomographic scanPositron emission tomographic scan
Positron emission tomographic scan
 
Dementia nmt
Dementia nmtDementia nmt
Dementia nmt
 
Clinacal applications of PET/CT vs PET/MRI
Clinacal applications of PET/CT vs PET/MRIClinacal applications of PET/CT vs PET/MRI
Clinacal applications of PET/CT vs PET/MRI
 
Brain PET imaging
Brain PET imagingBrain PET imaging
Brain PET imaging
 
Handbook of nuclear cardiology
Handbook of nuclear cardiologyHandbook of nuclear cardiology
Handbook of nuclear cardiology
 
Imagenes en lupus
Imagenes en lupusImagenes en lupus
Imagenes en lupus
 
Pet scan and thyroid scan
Pet scan and thyroid scanPet scan and thyroid scan
Pet scan and thyroid scan
 
Positron Emission Tomography (PET).pdf
Positron Emission Tomography (PET).pdfPositron Emission Tomography (PET).pdf
Positron Emission Tomography (PET).pdf
 
Emerging MRI and metabolic neuroimaging techniques in mild traumatic brain in...
Emerging MRI and metabolic neuroimaging techniques in mild traumatic brain in...Emerging MRI and metabolic neuroimaging techniques in mild traumatic brain in...
Emerging MRI and metabolic neuroimaging techniques in mild traumatic brain in...
 
Medical Imaging In Future Physician
Medical  Imaging In Future  PhysicianMedical  Imaging In Future  Physician
Medical Imaging In Future Physician
 
PET.pptx
PET.pptxPET.pptx
PET.pptx
 
Neuroimaging in dementia
Neuroimaging in dementiaNeuroimaging in dementia
Neuroimaging in dementia
 
Neruoimaging final
Neruoimaging finalNeruoimaging final
Neruoimaging final
 
PET and SPECT Scanning: Functional Brain Imaging
PET and SPECT Scanning: Functional Brain ImagingPET and SPECT Scanning: Functional Brain Imaging
PET and SPECT Scanning: Functional Brain Imaging
 
Clinical imaging and molecular biomarkers of drug resistant epilepsy.pptx
Clinical imaging and molecular biomarkers of drug resistant epilepsy.pptxClinical imaging and molecular biomarkers of drug resistant epilepsy.pptx
Clinical imaging and molecular biomarkers of drug resistant epilepsy.pptx
 
Fneur 12-601153
Fneur 12-601153Fneur 12-601153
Fneur 12-601153
 
Basics and principles of PET.pptx
Basics and principles of PET.pptxBasics and principles of PET.pptx
Basics and principles of PET.pptx
 
Diagnosis of CIDP
Diagnosis of CIDPDiagnosis of CIDP
Diagnosis of CIDP
 
Neuroradiology in dementia
Neuroradiology in dementiaNeuroradiology in dementia
Neuroradiology in dementia
 
The Expanding Role of Neuroimaging in Alzheimer’s Disease Diagnosis and Manag...
The Expanding Role of Neuroimaging in Alzheimer’s Disease Diagnosis and Manag...The Expanding Role of Neuroimaging in Alzheimer’s Disease Diagnosis and Manag...
The Expanding Role of Neuroimaging in Alzheimer’s Disease Diagnosis and Manag...
 

Recently uploaded

Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
Lighthouse Retreat
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
sisternakatoto
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
NEHA GUPTA
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
i3 Health
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 

Recently uploaded (20)

Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 

PET/MR imaging in neurodegenerative diseases

  • 1. The Current And Future Potential Applications Of PET/MR Imaging In Neurodegenerative Diseases By Dr. Walid Rezk, M.D. Lecturer of Radiodiagnosis Ain Shams University
  • 2.  Neurodegenerative disorders such as Alzheimer disease are among today’s most alarming health problems in our aging society.  The clinical assessment of neurodegenerative disorders benefits from recent innovations in the field of imaging technology.  These innovations include emerging tracers for molecular imaging of neuro-degenerative pathology and the introduction of novel integrated PET/MR imaging instruments. Introduction
  • 3.  Neurodegenerative diseases are characterized by a progressive and chronic loss of neural tissue in cognitive, motor, sensory, and other brain systems.  This entity of diseases includes: o Dementias o Parkinsonian syndromes including movement diseases such as multisystem atrophies (MSA), cortical-basal degeneration (CBD), and progressive supranuclear palsy (PSP) o Huntington disease (HD) o Amyotrophic lateral sclerosis (ALS) o Prion diseases like Creutzfeldt-Jakobdisease (CJD) Neurodegenerative disorders
  • 4.  In daily routine, most neurodegenerative diseases are diagnosed by a combination of clinical testing together with biomarkers, like brain imaging or cerebrospinal fluid analysis.  In brain imaging of neurodegenerative disease, MRI represents the standard tool. This is based on the high spatial resolution and the high soft tissue contrast this modality offers as well as the rather specific findings in at least some movement disorders such as MSA and PSP.
  • 5.  Often MRI is employed in suspected neurodegenerative diseases to exclude other non- neurodegenerative causes for the symptoms observed, like vascular disease, brain tumors, and traumatic or inflammatory brain changes.  In addition, certain brain atrophy patterns may support the clinical diagnosis of distinct neurodegenerative diseases.
  • 6.  Brain PET has also been used over many years to diagnose neurodegenerative diseases.  The main advantage of PET over MRI lies in its higher sensitivity to detect pathologies on a molecular level, which at least in principle permits more sensitive or even earlier diagnoses, because these diseases start with pathobiochemical processes that only lead to morphologic changes visible on MRI after a certain time period.
  • 7. Current PET Tracers to Image Neurodegenerative Diseases
  • 8.  It is evident that [18F]FDG, which is transported into intracellular space by glucose 1 transporters followed by phosphorylation via the hexokinase reaction, is the most often employed PET tracer in this regard.  [18F]FDG represents a universal marker of neuronal and synaptic integrity with relatively disease-specific uptake reduction patterns as for example:
  • 9. AD: bilateral temporoparietal areas are mainly affected exhibit [18 F]FDG uptake reductions.
  • 10. o Frontotemporal lobar degeneration (FTLD) in which, depending on its subtype, mainly frontal region or temporal region or both exhibit [18 F]FDG uptake reductions.
  • 11. o Parkinsonism: [18F]FDG-PET allows discrimination between primary PD and atypical parkinsonian syndromes, as major glucose consumption deficits being only found in the latter. o HD: mainly showing striatal uptake reduction o ALS: showing variable uptake reduction patterns depending on the ALS subtypes.
  • 12.  CJD: showing patchy uptake reductions of different patterns throughout the cortex and subcortical structures.
  • 13.  Apart from [18F]FDG, two groups of more disease- specific PET tracers are currently available in clinical routine: 1. Amyloid plaque tracers:  In AD, β-amyloid plaques, one of the histopathologically hallmarks of the disease, recently became traceable by PET tracers, like [18F] florbetapir, [18F] florbetaben, or [18F] flutemetamol.  These tracers are now approved for clinical use and are currently employed to show or exclude brain amyloid load in mild cognitive impairment (MCI), and early-onset clinical presentation of AD-like dementia.
  • 14. 2. PET tracers that target different components of dopaminergic transmission: Dopamine precursor tracer 3,4-dihydroxy-6-[18F]- fluorol-phenylalanine ([18F] FDOPA) The presynaptic dopamine transporter (DAT)- targeting [18F] fluoropropyl carbomethoxy iodophenylnortropane (FP-CIT) Both are used for clinical routine purposes to diagnose parkinsonian syndromes
  • 15.  In the scan of a disease-free brain, made with [18F]- FDOPA PET (left image), the red and yellow areas show the dopamine concentration in a normal putamen. Compared with that scan, a similar scan of a Parkinson’s patient (right image) shows a marked dopamine deficiency in the putamen.
  • 16. Current MRI Techniques to Image Neurodegenerative Diseases
  • 17. Disease Typical MRI Sequences Alzheimer disease T2 FLAIR and T1 3D GRE FTLD FLAIR and T1 3D GRE Vascular dementia FLAIR, T2*/SWI, and DWI DLB FLAIR and T1 3D GRE Parkinson disease T1, T2 multiplanar, and T2*/SWI Atypical parkinsonian syndromes T1, T2 multiplanar, and T2*/SWI Huntington disease T1, T2, and T2*/SWI ALS T1 and T2 CJD DWI, FLAIR, T1, and T2 Current Clinical Routine MRI Sequences to Image Neurodegenerative Diseases
  • 18. The routine MR imaging may reveal specific pattern of atrophy as in:  AD: Temporal atrophy patterns according to established scores (Scheltens score)
  • 19.  PSP: mesencephalic atrophy (mickey mouse sign)
  • 20.  Cerebellar MSA (formerly known as olivopontine cerebellar atrophy): pontine and cerebellar atrophy patterns combined with distinctive signs of pontine neurodegeneration (hot cross bun sign)
  • 21.  Advanced stages of HD: isolated putamen and caudate head atrophy
  • 22.  Hallervorden-Spatz disease, and occasionally PSP and CBD: iron accumulation with gliosis and spongiosis of the pallidum (eye-of- the-tiger sign)
  • 23.  Parkinsonian MSA (formerly known as MSA- striatonigral degeneration): periputaminal gliosis  CBD: unilateral atrophy of the primary motor cortex together with cortico-spinal tract degeneration
  • 24.  Diffusion-weighted MRI may show typical signal changes of the basal ganglia and cortex in CJD with greater visibility than on T2-weighted images owing to restricted diffusion with extracellular edema
  • 25. Combined PET/MRI to Image Neurodegenerative Diseases
  • 26.  Taking the aforementioned status and advantages of both PET and MR to image neurodegenerative diseases, it was a logical early step to clinically test the potential of combined PET/MRI technology in improving and simplifying neurodegeneration imaging.
  • 27.  One of the main technical challenges of integrated PET/MRI is to find a reliable substitute for the standard transmission-based (CT or line sources) attenuation correction (AC) of the PET data, a technique which is not available within combined PET/MRI systems.  In the current PET/MRI systems, AC of the PET data is mainly accomplished by using a 2-point Dixon MR sequence that segments tissues into four classes (lung, air, fat, and soft tissue) and is in some systems supplemented or substituted by an ultrashort echo time (UTE) sequence that provides additional bone contrast or segmentation.
  • 28.  An MR localizer precedes an approximately 20- minutes data acquisition interval in which a PET emission scan is simultaneously obtained with an array of MR sequences  Dixon or UTE sequences or both for AC of the PET data  T2 Fluid-attenuated inversion recovery sequence to decide on the extent of vascular lesions and atrophy Protocol of PET/MR examination
  • 29.  T2 turbo spin-echo sequences to give optimal contrast to infratentorial structures and to evaluate atrophy  Susceptibility-weighted sequence to detect microbleeds  T1-magnetization–prepared rapid acquisition gradient echo sequence for further, also quantitative, anatomical imaging and potential morphometric analysis. Protocol of PET/MR examination
  • 30.  Left two columns, represent amyloid PET/MR overlay together with the z- score map illustrating pathologic neocortical amyloid plaque burden (AD, DLB) or normal tracer uptake (VaD)  Middle column, the corresponding transverse anatomical T1-magnetization– prepared rapid acquisition gradient echo (MPRAGE) MR slice.  Right two columns, the corresponding transverse slices of other imaging modalities demonstrating biparietotemporal glucose consumption deficits (AD, DLB) or periventricular vascular lesions (VaD).
  • 31.  Severe bilateral hippocampal atrophy evident by severely reduced hippocampal volume (white arrows) (Left more than right) on Axial MRI images (A) With prominent bilateral frontal and temporal hypometabolism on axial fused PET MRI images (white arrowhead) (B and C). Note preserved parietal metabolism on axial and sagittal fused PET MRI images (white thick arrows) (D)
  • 32.  By obtaining all required imaging and biomarker information within one session, not just an improved convenience to the patients and their caregivers but also to the referring doctors is anticipated.  Furthermore, combined PET/MRI is expected to improve the diagnostic quality of both modalities by allowing simultaneous image data acquisition as well as a simplified and more accurate (owing to the perfect match between the PET and MRI data) image data analysis. Advantages of PET/MRI
  • 33.  Head movements during data acquisition can be online monitored by MRI, allowing for improved motion correction of the PET data.  Further, the MR information can be used to correct PET data for atrophy and partial volume effects.  Also, PET tracer uptake quantification can be improved by considering MRI-derived information on lean body mass, by creating an image-derived arterial input function, as well as by considering factors influencing brain tracer supply, like cerebral blood flow. Advantages of PET/MRI
  • 34.  Vice versa, the testing and evaluation of new MR techniques can be improved by validating them against simultaneously acquired PET gold standard techniques. Examples of that are ASL, which is tested in patients with dementia as a substitute for [18F] FDG, or quantitative susceptibility mapping as a potential substitute for amyloid PET tracers. Advantages of PET/MRI
  • 35.
  • 36. Future Potential of PET/MRI in Neuro-degenerative Diseases
  • 37.  For dementia imaging, there are promising new PET tracers as well as MR sequence developments.  For the PET component, the new emergence of tau tracers and α-synuclein tracers is attractive, as they will increase the possibilities to visualize different histopathologic hallmarks of different underlying dementias. Future Potential of PET/MRI in Dementia Diseases
  • 38.  Regarding newer potential MR techniques, especially diffusion-tensor imaging (DTI), resting-state functional MRI (rs-fMRI), and perfusion imaging are considered promising candidates to improve dementia diagnosis.  DTI maps showing white matter fiber integrity are able to provide models of structural brain connectivity, features that are often disturbed in neuro-degenerative diseases.  Rs-fMRI may provide complementary information about functional connectivity and allow functional cerebral network analysis.
  • 39.  Perfusion MRI, either traditionally using contrast- enhancement or arterial spin labeling (ASL), is another attractive approach.  In combination with amyloid PET tracers, at least in principle, the collection of information on both biomarker categories (amyloid load and neuronal injury) in AD within one session is possible
  • 40.  Novel PET tracers especially targeting DATs and α- synuclein are in development, potentially opening the way for a wider use of PET and PET/MRI as first-line imaging in these neurodegenerative diseases. Future Potential of PET/MRI in Parkinsonian Syndromes
  • 41.  For MRI, standard anatomical imaging as currently employed in most situations to detect specific atrophy patterns for different atypical parkinsonian syndromes might be enriched in the future by routine voxel-based morphometry and new techniques to detect and quantify white matter fiber degeneration and structural connectivity deficiency (DTI), and iron accumulation, for instance in midbrain or striatal areas (iron mapping)
  • 42. Future Potential of PET/MRI in Other Neurodegenerative Diseases  There are promising new developments regarding new PET tracers and novel MR sequences to improve imaging of these diseases.  Some of the new emerging PET tracers target neuroinflammatory processes known to occur in HD or ALS,  whereas others include more disease-specific processes like prion amyloid plaques in CJD.
  • 44.  The recently established combined PET/MRI technology has a great but yet mostly unexplored potential to improve early and differential diagnosis of many neuro-degenerative diseases.  New emerging PET tracers, like tracers that bind to β- amyloid, tau, or α-synuclein aggregates, as well as new MR techniques, like DTI, rs-fMRI, or ASL, will broaden the diagnostic capabilities of combined PET/MRI.
  • 45.  From the current knowledge on applying combined PET/MRI in neurodegenerative diseases, it is concluded that there is a chance of establishing this technique as routine first-line one-stop-shop clinical imaging tool.  Basic research into neurodegenerative diseases and antineurodegeneration drug testing are considered other promising applications of combined PET/MRI